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Abstract: Background: The standard treatment for hepatitis C virus
(HCV) infection is interferon, which is administered subcutaneously
and can have troublesome side effects. We evaluated sofosbuvir, an
oral nucleotide inhibitor of HCV polymerase, in interferon-sparing
and interferon-free regimens for the treatment of HCV infection.
Methods: We provided open-label treatment to eight groups of
patients. A total of 40 previously untreated patients with HCV geno-
type 2 or 3 infection were randomly assigned to four groups; all four
groups received sofosbuvir (at a dose of 400 mg once daily) plus riba-
virin for 12 weeks. Three of these groups also received peginterferon
alfa-2a for 4, 8, or 12 weeks. Two additional groups of previously
untreated patients with HCV genotype 2 or 3 infection received sof-
osbuvir monotherapy for 12 weeks or sofosbuvir plus peginterferon
alfa-2a and ribavirin for 8 weeks. Two groups of patients with HCV
genotype 1 infection received sofosbuvir and ribavirin for 12 weeks:
10 patients with no response to prior treatment and 25 with no pre-
vious treatment. We report the rate of sustained virologic response
24 weeks after therapy.
Results: Of the 40 patients who underwent randomization, all 10
(100%) who received sofosbuvir plus ribavirin without interferon
and all 30 (100%) who received sofosbuvir plus ribavirin for 12 weeks
and interferon for 4, 8, or 12 weeks had a sustained virologic
response at 24 weeks. For the other patients with HCV genotype 2
or 3 infection, all 10 (100%) who received sofosbuvir plus peginterfer-
on alfa-2a and ribavirin for 8 weeks had a sustained virologicJournal of Hepatology 20
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rapid virological response; RVR, rapid virologic response.response at 24 weeks, as did 6 of 10 (60%) who received sofosbuvir
monotherapy. Among patients with HCV genotype 1 infection, 21
of 25 previously untreated patients (84%) and 1 of 10 with no
response to previous therapy (10%) had a sustained virologic
response at 24 weeks. The most common adverse events were head-
ache, fatigue, insomnia, nausea, rash, and anemia.
Conclusions: Sofosbuvir plus ribavirin for 12 weeks may be effective
in previously untreated patients with HCV genotype 1, 2, or 3 infec-
tion. (Funded by Pharmasset and Gilead Sciences; ClinicalTrials.gov
number, NCT01260350).
 2013 European Association for the Study of the Liver. Published
by Elsevier B.V.
For the treatment of HCV infection, several direct-acting
antivirals (DAAs), including NS3 protease inhibitors, nucleoside/
nucleotide analogues and non-nucleoside inhibitors of the RNA-
dependent RNA polymerase, and NS5A inhibitors, are under
development [1]. Among them, sofosbuvir is a potent HCV-spe-
ciﬁc nucleotide analog (chain terminator). It is given orally, once
daily, without food effect. So far, no safety signal in preclinical/
clinical studies has been observed with this compound. Sofosbu-
vir has a high barrier to resistance with no virologic breakthrough
to date. It has a pangenotypic antiviral effect, although it might
be less efﬁcient in genotype 3 (G3).
The ELECTRON study goal was to evaluate the safety and efﬁ-
cacy of sofosbuvir as a backbone of combination antiviral therapy
in patients with chronic HCV genotype 1, 2, and 3 infections,
including both treatment-naïve and treatment-experienced
patients [2]. The design of the trial and the results are provided
in Fig. 1. Sofosbuvir combined with ribavirin (RBV) for 12 weeks
was associated with sustained virological response (SVR) in 100%
of G2/G3 HCV infected patients. For G1 HCV infected patients,
12-week sofosbuvir plus RBV provided SVR12 in 84% of
treatment-naïve, but only in 10% of null responders. For G2/3,
when sofosbuvir was given alone, SVR rate was 60%.
The authors concluded that sofosbuvir plus RBV may be an
effective treatment in all previously untreated patients with G2
or G3 HCV infections and also in the majority of G1 HCV naïve
infected patients.
What have we learned and what are the questions raised?
First, can we predict relapse with early viral kinetics with sof-
osbuvir based regimen? No, unfortunately. Previous studies with
pegylated-interferon (PegIFN) based therapy demonstrated that
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Fig. 1. Electron trial design and results [2]. ELECTRON is an open-label study with eight groups of patients. A total of 40 previously untreated patients with HCV genotype
2 or 3 infection were randomly assigned to four groups; all four groups received sofosbuvir (at a dose of 400 mg once daily) plus ribavirin for 12 weeks. Three of these
groups also received PegIFNa-2a for 4, 8, or 12 weeks. Two additional groups of previously untreated patients with HCV genotype 2 or 3 infection received sofosbuvir
monotherapy for 12 weeks or sofosbuvir plus PegIFNa-2a and ribavirin for 8 weeks. Two groups of patients with HCV genotype 1 infection received sofosbuvir and ribavirin
for 12 weeks: 10 patients with no response to prior treatment and 25 with no previous treatment. The rate of sustained virologic response 24 weeks after therapy is
reported.
JOURNAL OF HEPATOLOGYearly kinetics may help predict SVR [3]. However, in this sofosbu-
vir plus RBV trial, HCV RNA levels in all patients declined rapidly
after the initiation of treatment (Fig. 2). By week-2 of treatment,
the majority of patients from all groups had an undetectable level
of HCV-RNA. By week-4 of treatment, all 95 patients in the study
had an undetectable level of HCV RNA, which was maintained
until the end of treatment.
Second, is RBV useful? Yes. Results from the 10 patients with
G2 or G3 HCV infection who received sofosbuvir alone strongly
suggest a role for RBV in the maintenance of an antiviral
response. The exact mechanism by which RBV acts remains
unknown.
Third, can we extrapolate these data to phase 3 data or real-
world practice?
No, we still have to be cautious for several reasons: the num-
ber of patients is limited; they are selected as they have no cir-
rhosis, no comorbidities. We have to wait for more data, with a
larger number of patients, including difﬁcult-to-cure patients
with cirrhosis and previous non-response.
For G1, since sofosbuvir and ribavirin are not a reasonable
option, two strategies have been developed: (1) 12-week
sofosbuvir, PegIFN/RBV and (2) new IFN-free regimens with
sofosbuvir and ledipasvir (NS5A inhibitor).
Interestingly, several phase 3 studies with sofosbuvir based
regimen have been published since then.
The NEUTRINO trial was a single-group, open-label study of
sofosbuvir plus PegIFN/RBV in 327 patients infected with HCV
genotype 1, 4, 5, or 6 [4]. All patients received sofosbuvir, Peg-
IFNa-2a for 12 weeks. Most of the patients who were included
in the study had HCV G1 (89%); 9% had G4, and 2% had G5 orJournal of Hepatology 20136. Sofosbuvir was given orally at a dose of 400 mg, once a day,
along with RBV, also given orally in a dose based on body weight.
Patients who weighed less than 75 kg received 1000 mg/d, and
heavier patients received 1200 mg/d. Patients received Peg-
IFNa-2a subcutaneously once a week at a dose of 180 lg.
A total of 295 of the 327 patients (90%) reached SVR after
12 weeks of treatment. According to the HCV genotype: 89% of
patients with G1 (92% for G1a and 82% for G1b) and 96%
(27/28) of those with G4 had SVR. The single patient with G5
and all six patients with G6 in this trial had an SVR.
The FISSION trial was a randomized, open-label, active-control
study of sofosbuvir plus RBV in patients with G2 or G3 HCV infec-
tion; patients with the two genotypes were enrolled in an
approximately 1:3 ratio, respectively [4]. Patients were randomly
assigned to a 1:1 ratio to receive either 12 weeks of sofosbuvir
plus RBV or 24 weeks of PegIFN/RBV. The doses of sofosbuvir
and RBV were the same as those administered in the Neutrino
trial. The dose of RBV for patients in the PegIFN/RBV group was
800 mg daily. Sofosbuvir–RBV was shown to be non-inferior to
PegIFN/RBV. At 12 weeks, the rates of SVR for patients receiving
12 weeks of sofosbuvir–RBV and those receiving 24 weeks of Peg-
IFN/RBV were each 67%. An SVR occurred in 97% of patients with
G2 and in 56% of those with G3 in the group receiving sofosbuvir–
RBV, as compared with response rates of 78% and 63%, respec-
tively, in the group receiving PegIFN/RBV. Among patients with
cirrhosis at baseline, 47% of those receiving sofosbuvir–RBV had
an SVR, as compared with 38% of those receiving PegIFN/RBV.
The POSITRON trial was a double blinded, placebo-controlled
study that compared 12 weeks of treatment with sofosbuvir and
RBV with matching placebo in patients who had previouslyvol. 59 j 1342–1345 1343
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Fig. 2. Mean change from baseline in hepatitis C virus (HCV) RNA level during
treatment. All patients with HCV genotype 2 or 3 infection completed the
12 weeks of treatment. All patients had an HCV RNA level below the limit of
detection (i.e., <15 IU/ml) from week 4 until the end of treatment. Reprinted
from [2].
International Hepatologydiscontinued IFN-therapy owing to unacceptable adverse events,
who had a concurrent medical condition precluding therapy
with an IFN-containing regimen, or who had decided against
treatment with an IFN-containing regimen [5]. The most common
reasons that IFN treatment was not an option were clinically
signiﬁcant psychiatric disorders (in 57% of patients) and
autoimmune disorders (in 19%).
The rate of SVR at 12 weeks after treatment was 78% among
patients receiving sofosbuvir-RBV, as compared with 0% among
those receiving placebo (p <0.001). Among patients who received
sofosbuvir-RBV, 93% of patients with G2 HCV infection had an
SVR, as compared with 61% of those with G3 HCV infection. Like-
wise, 81% of patients without cirrhosis (92% of patients with G2
HCV infection and 68% of those with G3 HCV infection) had an
SVR, as compared with 61% of patients with cirrhosis (94% of
patients with G2 HCV infection and 21% of those with G3 HCV
infection).
The FUSION study was a blinded, active-control study involv-
ing patients who had not had a response to prior treatment with
an IFN-containing regimen [5]. Approximately 75% of the previ-
ously treated patients enrolled had either virologic breakthrough
during the prior treatment or virologic relapse afterward; the
remainder did not have a response. The rates of SVR achieved
were superior to the historical control rate of 25%, with rates of
50% in the 12-week group and 73% in the 16-week group
(p <0.001 for each comparison). Rates of SVR between the
groups showed that patients receiving 16 weeks of treatment
had a signiﬁcantly higher rate of SVR than patients receiving
12 weeks of treatment (p <0.001). The rates of SVR among
patients with G2 HCV infection who received 12 weeks of treat-
ment and those who received 16 weeks of treatment were 86%
and 94%, respectively, as compared with 30% and 62% for 12 and1344 Journal of Hepatology 201316 weeks of treatment, respectively, among patients with G3
HCV infection.
Cirrhosis was associated with a decreased rate of SVR, partic-
ularly among patients with G3 HCV infection who received
12 weeks of treatment. Among patients with cirrhosis who
received 12 weeks of treatment, the rate of SVR was 31% (60%
with G2 HCV infection and 19% with G3 HCV infection), as com-
pared with 61% among patients without cirrhosis (96% with G2
HCV infection and 37% with G3 HCV infection). Among patients
with cirrhosis who received 16 weeks of treatment, the rate of
SVR was 66% (78% with G2 HCV infection and 61% with G3 HCV
infection) as compared with 76% among patients without cirrho-
sis (100% with G2 HCV infection and 63% with G3 HCV infection).
So can we summarize these data? Yes, we can (Table 1). What
are the key messages?
First, for G1 HCV naïve patients, sofosbuvir with PegIFN-RBV
triple therapy appears a reasonable option. Of course, we will
need to increase the number of patients with cirrhosis; and also
data from genotype 1 experienced patients. There are ongoing
phase 3 studies to investigate the efﬁcacy and safety of sofosbu-
vir/ledipasvir ﬁxed-dose combination with or without RBV for 8
or 12 weeks in treatment-naive G1 HCV chronic infection. Ledi-
pasvir is an NS5A replication complex inhibitor ledipasvir (previ-
ously GS-5885).
Second, for G4 naïve patients, the data are excellent
but limited (n = 28 patients) and we need larger studies for this
speciﬁc G4 HCV population. There is a major medical
need since standard of care remains PegIFN-RBV for 48 weeks
with low SVR in ‘‘difﬁcult-to-cure’’ patient populations (IFNL3
non CC; patients with cirrhosis, experienced patients, etc.) [6].
We urge for studies in G4 HCV, naïve but also experienced
patients.
Third, for G2 HCV naïve patients, sofosbuvir-RBV provides
excellent results. We have to recall obvious evidence: G2 HCV
is not G3, and we need separate studies. In past PegIFN/RBV dual
therapy, for statistical issues, HCV G1 and G4, and HCV G2 and
G3, were respectively pooled [6]. For DAAs, we need an individual
study for each genotype. For G2 HCV treatment experienced and
cirrhosis, we need more data.
Four, data were disappointing regarding G3 HCV naïve
patients, in particular those with cirrhosis. The question is how
to treat HCV G3 infected patients in the near future. There will
be several options:
(1) PegIFN plus RBV, with satisfactory results, but with IFN
side effects.
(2) Sofasbuvir plus RBV for 16 weeks: (better tolerated, possi-
ble in case of IFN contra-indication, but not better than
PegIFN plus RBV, and even worse in cirrhotics).
(3) Sofosbuvir plus RBV for 24 weeks; however, SVR results
will be given by the ongoing VALENCE study.
(4) Triple therapy (Sofosbuvir plus PegIFN-RBV) with a short
duration of 12 weeks, using the neutrino regimen, but
without data with G3!
Moreover, it is believed that clinical trials provide best evi-
dence when they are randomized to controlled arms with large
number of patients [7]. Several of the trials discussed here lack
controlled arms or large number of patients. It may be argued
that controlled arms are not necessary when they expose patients
to side effects. Furthermore, we need data for «difﬁcult-to-cure»vol. 59 j 1342–1345
Table 1. Summary.
Study [Ref.] Patients population, n Treatment regimen Treatment duration SVR
NEUTRINO [5] G1, 4, 5, 6 
Naïve 
n = 327 
(G1 79%)
Sofosbuvir + PegIFN 
+ RBV
12 wk Total 90% (295/327)
G1a 92% (206/225)
G1b 82% (54/66)
G4 96% (27/28)
G5/6 100% (7/7)
Cirrhosis 80% (43/54)
FISSION [5] G2, 3 
Naïve 
n = 499 
(G3 72%) 
Sofosbuvir + RBV vs. 
P/R
12 wk sofosbuvir + 
RBV vs. 24 P/R
12 wk sof + RBV 24 wk P/R
Total 67% (170/253) 67% (162/243)
G2 97% (68/70) 78% (52/67)
G3 56% (102/183) 63% (110/176)
Cirrhosis 47% (23/49) 38% (19/50)
POSITRON [6] G2, 3 
IFN intolerant, 
ineligible or unwilling 
n = 278 
(G3 47%)
Sofosbuvir + RBV vs. 
placebo
12 wk Total 78% (161/207)
G2 93% (101/109)
G3 61% (60/98)
Cirrhosis 61% (19/31)
FUSION [6] G2, 3 
Treatment-
experienced 
n = 201 
(G3 63%)
Sofosbuvir + RBV 12 or 16 wk 12 wk 16 wk
Total 50% (50/100) 73% (69/95)
G2 86% (31/36) 94% (30/32)
G3 30% (19/64) 62% (39/63)
Cirrhosis 31% (11/36) 66% (21/32)
P/R, PegIFN/RBV; sof, sofosbuvir.
JOURNAL OF HEPATOLOGYpatients, those with cirrhosis, previous non response, comorbidi-
ties, etc.
Impressive data have been reported with sofosbuvir based
therapy, with high SVR rates and a favorable safety proﬁle so far.
A pilot study demonstrated that addition of ledipasvir increased
efﬁcacy of sofosbuvir plus RBV, without additional safety issues,
and without virologic failures. Gilead recently initiated the ﬁrst
Phase 3 trial (ION-I) evaluating a ﬁxed-dose combination of sof-
osbuvir and lepidasvir in treatment-naïve G1 HCV infected
patients. This four-arm study is evaluating the ﬁxed-dose combi-
nation with and without RBV for 12-and 24-week durations in
800 patients, 20 percent of whom have evidence of cirrhosis.
Finally, there is a realistic hope for patients with HCV infec-
tion, since several IFN-free trials are ongoing with promising
early data [8–11]. We do hope that the majority of patients with
HCV infection will become «easy-to-cure», and there will be
increase in access to treatment.Conﬂict of interest
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